Although CD4+ cell numbers alone do not directly correlate with clinical outcome in GBM patients [7,14], new evidence suggests that elevated CD4+ and/or CD4+FOXP3+ population ratios may be indicative of glioma disease severity and risk of recurrence [15,16]. Here, FOXP3 is linked to central nervous system cancer.